MGMT and central nervous system cancer: Papachristodoulou et al. reported that a liposomal O6BTG can efficiently target MGMT, thereby sensitizing murine and human glioma cells to TMZ in vitro and magnetic resonance image-guided microbubble-enhanced low-intensity pulsed focused ultrasound mediates the delivery of the stable liposomal MGMT inactivator into the tumor region resulting in complete MGMT depletion in vivo (79).